3-Deoxy 3-Chloro Abiraterone
✓
100% accuracy
of data
24/7 scientific
support
⬡
0% tolerance in
quality of product

Stock Locations

  • New Jersey, USA
  • Czech Republic, EU
  • Mumbai, India

* Stock subject to availability.

3-Deoxy 3-Chloro Abiraterone

● Under Development

Catalogue No.:VL830022
CAS No.:N/A
Mol. Formula:C24H30ClN
Mol. Weight:367.95 g/mol

Additional information on 3-Deoxy 3-Chloro Abiraterone

Parent drug

Abiraterone

IUPAC Name

1-((8R, 9S, 10R, 13S, 14S)-10, 13-Dimethyl-17-(pyridin-3-yl)-2, 7, 8, 9, 10, 11, 12, 13, 14, 15-decahydro-1H-cyclopenta[a]phenanthren-3-yl)ethan-1-one

Pharmacopoeial Synonyms

N/A

Other Synonyms

N/A

Smiles

C[C@@]12C(C3=CC=CN=C3)=CC[C@@]1([H])[C@]4([H])CC=C5CC(Cl)CC[C@]5(C)[C@@]4([H])CC2

InChI

InChI=1S/C24H30ClN/c1-23-11-9-18(25)14-17(23)5-6-19-21-8-7-20(16-4-3-13-26-15-16)24(21,2)12-10-22(19)23/h3-5,7,13,15,18-19,21-22H,6,8-12,14H2,1-2H3/t18?,19-,21-,22-,23-,24+/m0/s1

Description

The compound 3-Deoxy 3-Chloro Abiraterone is a thoroughly characterized reference standard that complies with rigorous regulatory guidelines, including those from USP, EMA, JP, and BP. It is ideal for critical applications such as analytical method development, method validation (AMV), and quality control (QC), especially in the production of Abiraterone. Designed to support both Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA), this product delivers the precision required for reliable results. Additionally, it includes a detailed Structure Elucidation Report (SER), ensuring accuracy and dependability for advanced analytical purposes. 3-Deoxy 3-Chloro Abiraterone or 1-((8R,9S,10R,13S,14S)-10,13-Dimethyl-17-(pyridin-3-yl)-2,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-yl)ethan-1-one, it is poorly absorbed and is susceptible to hydrolysis by esterases and is an orally active inhibitor of the steroidal enzyme CYP17A1 that is used in the treatment of prostate cancer.

References

Goldberg, Tamara, and Evangelina Berrios-Colon. “Abiraterone (Zytiga), a Novel Agent for the Management of Castration-Resistant Prostate Cancer.” Pharmacy and Therapeutics, vol. 38, no. 1, 1 Jan. 2013, pp. 23–26, www.ncbi.nlm.nih.gov/pmc/articles/PMC3628169/.

Request a Quote

« * » indique les champs nécessaires

Ce champ n’est utilisé qu’à des fins de validation et devrait rester inchangé.
Products quotation
Name
Url